---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041323"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:08:55.649565+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)

## Summary
- Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.
- Operating profit of $1.9M, up 78.1% from prior-year period.
- Net income attributable to common shareholders: $14.9M, an 886% increase.
- Growth driven by launch of Elite Laboratories label product line in June 2023 quarter.
- Conference call scheduled for Nov 15, 2023 at 11:30 AM EST.

## SEC filing metadata
- accession: 0001493152-23-041323
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/0001493152-23-041323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041323
- JSON: https://secwatch.observer/filing/0001493152-23-041323.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041323.txt

## Key facts
- Earnings Releases
  ELITE PHARMACEUTICALS INC /NV/ reported the second quarter of fiscal year 2024 ended September 30, 2023 results: revenue $14.2 million, net income $14.9 million.
  - Period: the second quarter of fiscal year 2024 ended September 30, 2023
  - Revenue: $14.2 million
  - Net income: $14.9 million
  - Result: reported results
  source text: Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/0001493152-23-041323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.